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Abstract 
Septic shock is the body' s inflammatory response to an infection, and is usually 
associated with gram negative bacteria. It is characterized by hypotension and 
hypoperfusion, despite adequate fluid resuscitation, and can lead to multiple organ 
failure. At these advanced stages there is a high morbidity and mortality rate associated 
with it. One mediator of this inflammatory response is a lipopolysaccharide (LPS), or 
endotoxin, found in the gram negative bacterial cell wall. 
Besides having effects on the body as a whole, there are many cellular processes 
affected by endotoxin. In the body, there is a family of enzymes, the cytochrome P450 
enzymes, which are the body's drug metabolizing enzymes. Although found in all tissue 
types, the P450 enzymes are mainly located in the liver. There are many families and 
isoforms of these enzymes, of which several are inhibited by endotoxin. The regulation of 
the P450 enzymes is very complex. During the systemic inflammatory response to 
endotoxin, many cytokine mediators are released into the bloodstream. These mediators, 
specifically tumor necrosis factor-a, interleukin-I , and interleukin-6, all are capable of 
regulating the activity, and production of the P450 enzyme system. 
Lidocaine is a widely used antiarrhythmic drug, which is metabolized by 
cytochrome P450 enzymes, to its major metabolite monoethylglycinexylidide (MEGX). 
Lidocaine is metabolized specifically by P450 3A2, 2Cl 1, and 2B 1 in the rat. The 
conversion of lidocaine to MEGX has been looked at as a method of evaluating liver 
function or dysfunction in a variety of liver related diseases, including viral hepatitis, 
cirrhosis, liver transplantation, and hypovolemic shock. 
II 
This present study was undertaken to determine whether the conversion of 
lidocaine to MEGX was inhibited in vivo, in rats given a lethal dose of endotoxin. It was 
hoped that the degree of drug metabolizing inhibition could be determined using this 
whole animal model, since many of the systemic effects of septic shock, i.e. hypotension, 
also factor into the clearance of a high extraction compound, like lidocaine. Results from 
this study could potentially be helpful in determining drug metabolizing alterations in 
humans experiencing septic shock. 
ii 
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Abstract 
Gram-negative bacterial endotoxin causes a systemic inflammatory 
response, known as sepsis. High exposure to endotoxin can lead to septic shock, which is 
characterized by hypoperfusion and hypotension, which can ultimately lead to multiple 
organ failure, and death. One of the organs highly effected by endotoxin is the liver. The 
liver has a family of enzymes, the cytochrome P450 enzymes, which handle the 
biotransformation of many xenobiotics, to excretable compounds. Endotoxin inhibits this 
biotransformation by inhibiting and down regulating many P450 isoforms. This paper 
describes a study into the metabolism of lidocaine during a endotoxin induced shock. 
Lidocaine is metabolized via P450 enzymes, to MEGX, the major metabolite. Serum 
concentrations of lidocaine and MEGX were analyzed at various time points. Blood 
pressure measurements were also taken to determine if hypotension played any role in 
reduced lidocaine clearance. 
A lethal dose of endotoxin caused severe hypotension eight hours after 
administration (mean±SEM; 51. 7±50. 7) when compared to control animals (mean±SEM; 
108±9. 5). Endotoxin significantly inhibited the clearance of lidocaine in vivo at 120 
minutes (mean±SEM: 1.16±0.52) when compared to control animals (mean±SEM; 
0.08±0.067) (p<0.05). The degree of inhibition was greater than cimetidine treated 
animals (mean±SEM; 0.15±0.073) though, which is a positive control for P450 
inhibition, suggesting that the reduc5ion of blood pressure could possibly be a factor in 
the clearance (p<0.05). The serum level MEGX was elevated in the endotoxin treated 
animals (mean±SEM; 626.8±123.2) compared to control (mean±SEM; 137.5±44.2) and 
cimetidine animals (mean± l6 l.1±71. l) at 120 minutes (p<0.05). It is possible that the 
elevated concentration of metabolite in the serum of septic animals is the result of 
reduced clearance of metabolites secondary to blood flow in the kidneys, and/or reduced 
bile flow. Since the serum MEGX did not appear to reflect the decreased lidocaine 
clearance, ratios of lidocaine:MEGX were calculated. A significant difference between 
the endotoxin treated and cimetidine treated groups was seen at 15 minutes was seen 
(p<0.05). The ratio of lidocaine:MEGX appears to be a potential measure of inhibition of 
drug metabolism, but further exploration in this model is needed. 
2 
Introduction 
Lidocaine, is the most widely used intravenous anti-arrhythmic agent for the 
management of acute ventricular arrhythmias. (Zito, et. al., 1978) Lidocaine is totally 
and rapidly metabolized in the liver, (Bennet, et. al. , 1982; Keenaghamp, et. al., 1972) 
with one of its major metabolites produced by oxidative N-deethylation to 
monoethylglycinexylidide (MEGX). (Nyberg, et. al., 1977) It has been postulated that 
the conversion of lidocaine to MEGX be used as a marker of liver function and drug 
metabolism during different disease states. It has been shown that after administration of 
lidocaine, serum MEGX levels at 15 minutes is a sensitive and specific indicator of 
hepatic damage, (Berdelski, et. al., 1987; Oellerich, et. al. , 1987) compared to 
indocyanine green and galactose. (Burdelski, et. al., 1988) Lidocaine and its metabolism 
has been suggested as a way to monitor pre-transplant liver function (Oellerich, et. al. , 
1987; Schroeder, et. al., 1989) and as an early predictor of rejection in transplant 
recipients. (Schroeder, et. al. , 1989) MEGX formation can also be used for the rapid 
assessment of liver function in cirrhosis, (Oellerich, et. al. , 1990) and after hypovolemic 
shock. (Chandel, et. al. , 1995) 
Sepsis is the developed condition of the body's systemic inflammatory response 
to the presence of an infection in the body by a microorganism, most frequently derived 
from gram-negative bacteria. When sepsis further deteriorates, septic shock can result. 
Shock is frequently associated with poor circulation, hypotension and hypoperfusion, and 
can lead to multiple organ failure. A number of studies have shown that there is severe 
liver dysfunction following sepsis. (Wang, et. al. , 1995; Wang, et. al. , 1991) Hepatic 
function and effective hepatic blood flow, as measured by clearance of indocyanine 
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green, was decreased in studies using the cecal ligation and puncture septic animal 
model. (Wang, et. al., 1991; Wang, et. al., 1995) The activity of the cytochrome P450 
drug metabolizing enzyme system also changes in sepsis. It has been shown in rats and 
mice, that after endotoxin administration, P450 2B l (Stanley, et. al., 1988), 2Cl l 
(Morgan, 1989; Sewer, et. al., 1996; Morgan, 1993), 2C 12 (Morgan, 1993), 2C6 
(Morgan, 1993), 2C7 (Morgan, 1993), 3A2 (Sewer et. al., 1996) and 2El(Morgan, 1993; 
Sewer et. al., 1996) are suppressed.(Ishikawa, et. al., 1991) Also, it has been shown that 
there is a significant decrease in drug metabolism in human subjects exposed to 
significantly smaller dose of endotoxin than would be expected in a clinical case of 
septic shock. (Shedlofsky, et. al., 1996) 
Systemically, endotoxin has profound effects on the heart, other organs and the 
vasculature, with a major cause of morbidity associated with a hypotensive state, which 
persists despite adequate fluid resuscitation. (Parillo, et. al., 1993) Endotoxin also 
inhibits P450 activity, including the enzymes that metabolize lidocaine, P4502B 1, 
P4502Cl 1, and P4503A2, which have the highest MEGX formation turnover in the rat. 
(Oda, et. al., 1989; Imaoka, et. al., 1990; Nakamoto, et. al., 1997) Although it has been 
shown that endotoxin inhibits these P450 isoforms, and that these isoforms are 
responsible for the metabolism of lidocaine to MEGX, lidocaine metabolism during 
septic shock has not been studied. Since MEGX formation has been considered as a 
model for liver dysfunction in cirrhosis (Oellerich et. al ., 1990), hypovolemic shock 
(Chandel, et. al., 1995) liver transplantation (Oellerich et. al., 1989; Schroeder et. al. 
1989), ischemic liver injury (LeClercq, et. al, 1997) and chronic viral hepatitis (Elin, et. 
al., 1997), we examined if MEGX formation was a good marker for the metabolic 
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changes induced by endotoxin. It is thus needed to examine the metabolism of lidocaine 
to MEGX in the in vivo animal model, where the blood pressure, and subsequent liver 
blood flow are dramatically different between septic and control animals. 
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Materials and Methods 
Experimental protocols were approved by the Institutional Animal Care and Use 
Committee of the University of Rhode Island. All reagents were purchased from Sigma 
Chemical, with the exception of the lipopolysaccharide, purchased from Difeo 
Laboratories, and the TDx analyzer kits, which were graciously supplied by Abbott 
Laboratories. 
Male Sprague Dawley rats, ranging from 250-550g, were administered endotoxin 
or cimetidine. Endotoxin (E. Coli 026 :B6 LPS, lot #91608), 45.6 mg/kg, was injected IP 
approximately 5 hours before surgery. Cimetidine, 80mg/kg, was injected IP daily for 
three days prior to surgery. This group served as a positive control for inhibition of 
cytochrome P450 (Levine, et. al ., 1998; Bruck, et. al. , 1990; Froncillo, et. al. , 1983) 
Initial blood pressure readings and lidocaine administration occurred at six hours after 
endotoxin injection, which was 24 hours after the third cimetidine injection. 
In Vivo Study of Blood Pressure 
Rats, weighing 250-550 g, were anaesthetized with pentobarbital (50 mg/kg) . A 
mid-line incision from the chin to the upper part of the thorax was made so that both the 
trachea and left carotid artery could be cannulated. A short cannula was secured in the 
trachea, while a cannula, filled with a 10 units/ml heparin/saline solution, attached to a 1 
mL syringe, was secured into the artery. An infusion of 0.4 mL of the heparin/saline 
solution was made, and the rat was allowed to stabilize for 30 minutes. After the rat had 
stabilized, blood pressure recordings were taken at 0, 60, 90, and 120 minutes using a 
Statham P-23A transducer, and recorded on a Grass Model 7 Polygraph. 
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In Vivo study of Lidocaine Metabolism 
Lidocaine (2mg/kg) was administered via the cannula at time zero . The catheter 
was then flushed with 0.3 m.L of saline. Blood, 0.4 m.L, was drawn via the cannula at 
times 15, 25, 45, 60, 90, and 120 minutes, and centrifuged at 3,000 x g for 3-5 minutes to 
collect the serum. After each blood withdrawal, the animal was infused with the same 
amount of saline to make up for fluid loss. Serum samples were analyzed for lidocaine 
and its major metabolite monoethylglycinexylidide (MEGX) using a fluorescence 
immunoassay (TDx). (Abbott Diagnostics, Abbott Park, Illinois) The standard curve was 
linear between 0 and 10 µg/m.L for lidocaine, and 0-250 ng/mL for MEGX. Coefficients 
of variation for each of these assays were 10% at all control concentrations. 
Statistical Analysis 
Repeated measures ANOVA was used to compare blood pressure data. After a 
significant overall difference was found , a Student-Newman-Keuls method was used as 
the pairwise multiple comparison procedure. All lidocaine and MEGX data was tested 
with a one-way ANOVA, and after a significant difference was found , a Tukey ' s multi-
comparison post hoc test was used. Significance was determined by a p value of <0.05. 
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Results 
Endotoxin had a detrimental effect on the blood pressure. (Figure l) There was a 
significant decrease in blood pressure between the endotoxin and the control groups at 90 
and 120 minutes (p<0.05) and between the endotoxin and the cimetidine groups at 90 and 
120 minutes (p<0.05). The average blood pressure of the endotoxin group dropped from 
105±23 .5 mmHg, at time zero, to 51.7±50.7 mmHg two hours later, while the blood 
pressures of the untreated and cimetidine group stayed constant throughout the 
experiment. The average blood pressure at eight hours after endotoxin administration 
decreased by approximately 50% of the untreated and cimetidine groups. The blood 
pressures of the endotoxin group at 60, 90, and 120 minutes were significantly lower than 
the blood pressures at time zero (p<0.05). After examination of blood pressure data of 
the endotoxin group, two sub-populations of endotoxin treated rats were distinguished; 
those that showed a drop in blood pressure (n=4), and those that were unaffected (n=3). 
(Figure 2) These two groups were significantly different at time points 90, and 120 
minutes (p<0.05). The animals whose blood pressure dropped were significantly 
different versus the control group at 90 and 120 minutes (p<0.05). 
Lidocaine elimination was significantly lower than the untreated and cimetidine 
groups at 120 minutes after administration (p<0.05). (Figure 3) At 120 minutes after 
lidocaine administration, the endotoxin group had a 14.5 fold and 7.5 fold higher 
concentration of lidocaine than the untreated and cimetidine groups, respectively. The 
cimetidine group had a 1. 9 fold greater lidocaine concentration than the untreated group. 
MEGX concentrations were determined at the same time points as lidocaine. 
(Figure 4) MEGX serum levels increased during the first 60 minutes after lidocaine 
administration and then began to plateau for the last 60 minutes of the experiment in the 
control groups, while in the endotoxin group, MEGX concentrations continued to 
increase throughout the experiment. The concentrations in the endotoxin group were 
significantly higher than control and cimetidine groups at all time points except 15 
minutes (p<0.05). The endotoxin group had a 3.4 fold greater concentration ofMEGX 
than the untreated group, and a 2.9 fold higher level than the cimetidine, at 120 minutes 
after lidocaine administration. The cimetidine group had a slightly higher serum level of 
ivIBGX than the untreated group, but the average difference in concentration between the 
two groups was approximately 24 ng/mL, and was found insignificant. 
Lidocaine:ivIBGX ratios were derived to normalize the effects of endotoxin on the 
changes of lidocaine concentration on MEGX formation. (Figure 5) At 15 minutes there 
was a significant difference between the lidocaine:ivIBGX ratio for the endotoxin group 
and the control group(p<0.05). Significant differences were also shown at 15 minutes 
between the endotoxin and cimetidine groups (p<0.05), and the cimetidine and control 
groups (p<0.05). At later time points, the lidocaine:MEGX ratio of the endotoxin group 
at 120 minutes was 5.6 fold higher than the untreated group, and twice that of the 
cimetidine group. The cimetidine group had a lidocaine:MEGX ratio that was 2.5 fold 
higher than the untreated at the same time point. 
In order to examine the effect of blood pressure on the concentration of lidocaine 
and MEGX, we divided the endotoxin group into those that had a significant blood 
pressure decrease (shock) , and tho~~ that showed no effect on blood pressure (non-
shock) . The two groups were examined for changes in MEGX and lidocaine 
concentrations. Lidocaine concentrations for the group whose blood pressures dropped 
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had a 1.5 fold larger lidocaine serum level at 120 minutes after lidocaine administration, 
compared to the group whose blood pressures did not change, but the changes were not 
significant at the p<0.05 level. (Figure 6) MEGX levels were significantly higher for 
both the shock and non-shock at 45, 60, 90, and 120 minutes compared to control animals 
(p<0.05). The non-shock group and the control group were significantly different at 25 
minutes (p<0.05). At 120 minutes, average MEGX concentrations were 128% higher for 
those that were not in shock compared to those in shock at 120 minutes. (Figure 7) The 
ratio of lidocaine:MEGX was approximately twice as great for the shocked compared to 
non-shocked animals. (Figure 8) At 15 minutes there was a significant difference 
between the shock and non-shock sub-groups (p<0.05) and between the shock and 
control group (p<0.05). These data suggest that blood pressure may have an effect on the 
clearance of lidocaine and MEGX. 
I 0 
Figure 1. Blood pressures (mmHg) of untreated (n=5), cimetidine (n=5, 80 mg/kg, for 
three days), and endotoxin (n=7, 6 hours pre-treatment with endotoxin, LD 100) treated 
animals, over two hours. The blood pressures were measured on a Stratham polygraph in 
mmHg (* p<0.05 LPS vs . Control at 90 and 120 minutes)(+ p<0.05 LPS vs. Cimetidine 
at 90 and 120 minutes) (- p<0.05 LPS vs. Time 0 at 90 and 120 minutes). Means± SEM 
are reported. 
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Figure 2. Blood Pressures (mmHg) of the two sub-populations of endotoxin treated rats 
(six hour pre-treatment, LD100), shock (n=4), and non-shock(n=3), over the course of two 
hours. Blood pressures are measured in mmHg (* p<0.05 shock vs. non-shock at 90 and 
120 minutes)(+ p<0.05 Shock vs. Control at 90 and 120 minutes) (- p<0.05 Shock vs 
Time 0 at 60, 90, and 120 minutes) . Means± SEM are reported. 
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Figure 3. Lidocaine concentrations of untreated (n=5), cimetidine (n=5, 80 mg/kg, for 
three days) and endotoxin (n=7, six hour pre-treatment, LD 100) groups over a course of 
two hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 
25, 45, 60, 90, and 120 minutes after dosage(* p<0.05 LPS vs. Control at 25, 45,60,90, 
and 120 minutes)(+ p<0.05 LPS vs. cimetidine at 45, 60, 90, and 120 minutes). Means± 
SEM are reported. 
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Figure 4. MEGX concentrations of untreated (n=5), cimetidine (n=5, 80 mg/kg. For three 
days) and endotoxin (n=7, six hour pre-treatment, LD100) groups over a course of two 
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 
45, 60, 90, and 120 minutes after dosage. Serum samples were assessed for 
monoethylglycinexylidide (MEGX), the major metabolite of lidocaine (* p<0.05 LPS vs. 
Control at 15, 25,45, 60, 90, and 120 minutes)(+ p<0.05 LPS vs. Cimetidine at 15, 25, 
45, 60, 90, 120 minutes) . Means± SEM are reported. 
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Figure 5. Ratio of Lidocaine:MEGX of untreated (n=5), cimetidine (n=5, 80 mg/kg, for 
three days) and endotoxin (n=7, six hour pre-treatment, LD 100) groups over a course of 
two hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 
25, 45, 60, 90, and 120 minutes after dosage(* p<0.05 LPS vs. Cimetidine at 15 
minutes) . Means± SEM are reported. 
19 
400 
----- Untreated 
-0- Cimetidine 
~ Endotoxin 
300 
x (') 
w 
~ 
- 200 Q) 
c 
ro 
u 
0 
TI 
_J 
100 
0 
0 20 40 60 80 100 120 140 
Time (Minutes) 
20 
Figure 6. Lidocaine concentrations of the two sub-populations of endotoxin treated rats 
(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two 
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45, 
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 45, 60, 90, and 120 
minutes)(+ p<0.05 Non-Shock vs. Control at 45, 60, 90, and 120 minutes). Means± 
SEM are reported. 
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Figure 7. MEGX concentrations of the two sub-populations of endotoxin treated rats 
(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two 
hours . Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45, 
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 15, 25, 45, 60, 90, 
and 120 minutes)(+ p<0.05 Non-shock vs. Control at 15, 25, 45, 60, 90, and 120minutes) 
(-p<0.05 Non-shock vs. Shock at 25, 45, 60, and 90 minutes). Means± SEM are 
reported. 
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Figure 8. Lidocaine/MEGX ratios of the two sub-populations of endotoxin treated rats 
(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two 
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45, 
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 15, 60, and 120 
minutes)(+ p<0.05 Non-Shock vs. Control at 15 min) . Means± SEM are reported. 
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Discussion 
There was a significant decrease in the blood pressure between the untreated and 
endotoxin groups. Many previous models have examined the effects of low dose 
endotoxin administration chronically and acutely. (Fish, et. al., 1986; Keeler, et. al. , 
1981; Dedichen, 1972; Suffredini, et. al., 1989) Although these models showed some 
effect of low dose endotoxin on hemodynamics, we were interested in the effects of a 
100% lethal dose, and the immediate effects on blood pressure. Previous studies in rats 
using a low dose of endotoxin, 1 mg/kg/day, elicited insignificant drops in mean arterial 
pressures after 6 hours, but after 30 hours of chronic administration there was a 
significant change in pressure. (Fish, et. al., 1986) Keeler, et. al. found no significant 
change in mean arterial pressure after an acute 4 hour infusion of 2.5 mg/kg/hr endotoxin, 
but saw significant changes after a chronic infusion of 2.4-2. 9 mg/kg over 4 days. 
(Keeler, et. al., 1981) In a canine model, aortic blood pressures dropped between control 
and endotoxin animals one hour after endotoxin administration, and continued to fall over 
the course of the next six hours. (Dedichen, 1972) Endotoxin response on blood pressure 
has been shown to significantly decrease mean arterial pressure after five hours in 
humans. (Suffredini, et. al., 1989) Although blood pressure changes occurred in these 
previous experiments, the degree of magnitude was less than that seen in this experiment. 
This can be attributed to the differences in dosages between experiments, and leads us to 
believe that an extremely large do~~ of endotoxin can cause severe and lethal hypotension 
within eight hours after administration. 
Two distinguishable sub-populations of endotoxin rats were shown, shocked and 
non-shocked. The non-shocked animals had very small decreases in pressure, less than 
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20 mmHg, which were comparable to the insignificant acute responses of blood pressure 
to endotoxin previously seen. (Fish, et. al. , 1986; Keeler, et. al. , 1981) The shocked 
animals had blood pressures so low that life was unsustainable after the eight hours. 
The clearance of lidocaine from the serum was reduced in the endotoxic model. 
After 20 minutes, the endotoxin group showed very little change in lidocaine 
concentrations, compared to the control groups. This reduction in clearance could 
possibly be due to alterations in the liver enzymes reducing the rate of lidocaine 
metabolism. Lidocaine is metabolized via P4502Cl1, 2Bl, and 3A2 to MEGX in the 
rat. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990) In normal rats the 
levels of2Cl 1 and 3A2 are 139 and 84 pmol/mg protein, compared to 6.9 pmol/mg 
protein for 2B 1. (Nakamoto et. al., 1997) Nakamoto, et. al ., showed that upon induction 
of liver enzymes with phenobarbital, the rate at which MEGX is formed is increased. 
2B 1 levels were increased to 360 pmol/mg protein, and 3A2 levels rose to 390 pmol/mg 
protein, while 2C 11 levels stay the same. This suggests that the more 2B 1 and 3A2 there 
is in the rat liver, the greater the formation of MEGX in vivo will be. (Nakamoto, et. al. , 
1997) It has been shown in rats that after six and twelve hours, P4502C 11 (Morgan, 
1989) and P4503A2 (Sewer, et. al. , 1996) respectively are down regulated after a single 
1 mg/kg dose of endotoxin. P450 2B 1 was also inhibited in mice by low dose endotoxin 
as well. (Stanley, et. al. , 1988) It is known that the systemic response to endotoxin is 
expressed by a variety of cytokine mediators. Using a higher dose of endotoxin than used 
in. previous experiments, it could b~ assumed that there would be a much larger systemic 
response. Upon this assumption one might assume a greater degree of down-regulation 
of P450 due to the increase of cytokine mediators, leading to greater inhibition. 
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Cimetidine was used as a positive control of P450 inhibition because it has been 
shown in rat to inhibit lidocaine clearance in vivo (Fruncillo, et. al., 1983), and in the 
perfused liver. (Bruck, et. al., 1990) This inhibition in lidocaine clearance was seen, 
however, the resultant decrease in lidocaine clearance was only intermediate to that 
shown by endotoxin. The specificity of metabolism of the P450 isoenzymes may explain 
the lower lidocaine clearance in the endotoxin animals. Cimetidine has been shown to 
inhibit 2Cl 1, but not members of the 2B or 3A family in rats. (Levine, et. al., 1998) In 
untreated animals, lidocaine metabolism to its major metabolite, tvffiGX, is dependent on 
both 2Cl 1 and 3A2. (Nakamoto, et. al., 1997) Therefore, only one of the two main 
isoforms of P450 responsible for lidocaine metabolism is inhibited. Thus, cimetidine 
would have less of an effect on lidocaine clearance than during endotoxic shock where 
both forms are inhibited. Endotoxin inhibits P450 isoforms responsible for lidocaine 
metabolism, but physiologic changes in the hemodynamics also might intensify the 
alterations seen. 
Hepatic blood flow is an important aspect of lidocaine elimination, and clinical 
manifestations that reduce hepatic blood flow would also be expected to rate lidocaine 
would be eliminated. (Zito, et. al. , 1978) Indocyanine green (ICG) elimination is 
dependent exclusively on hepatic blood flow. (Zito, et. al. , 1978) It has been shown 
using a different model of sepsis, cecal ligation and puncture (CLP), that hepatic blood 
flow increases at early time points .(2-10 hours), but is markedly decreased after 20 hours. 
(Wang, et. al. , 1991) The later time points, those after 16 hours, of the CLP model are 
similar to the high dose endotoxin model in this study in that they both represent a 
hypodynamic model of sepsis. Hepatocellular dysfunction, tested by ICG clearance, was 
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seen at both the early and later time points with a higher degree of dysfunction at 20 
hours. (Wang, et. al., 1991) Since lidocaine in this study was distributed via the hepatic 
artery, a decrease in blood flow could significantly alter the clearance of the drug from 
the blood . 
The concentration of MEGX was significantly higher in septic animals compared 
to control and cimetidine, and cimetidine animals compared' to controls. During the early 
time points all three groups have an increasing slope, but while the slopes of the 
cimetidine and control groups level off at later time points, the MEGX levels of the 
endotoxin group still increase at these later time points. It has been shown in the acute 
and chronic endotoxic rat there is a decrease in renal blood flow. (Fish, et. al., 1986) 
Endotoxin also results in impaired renal oxygenation and perfusion in the dog model, 
which is due to central hypotension and the local effects of endotoxin on the kidney. 
(Gullichsen, et. al., 1989) The decrease of renal blood flow, and the resultant renal 
failure, may be a cause of the accumulation ofMEGX in the serum at the later time 
points. These data seem rather anomalous when looked at in conjunction with the 
lidocaine concentrations. A possible reason for the increased concentration of MEGX 
could be due to liver cell dysfunction and the poor elimination of drug metabolites from 
the blood. 
During sepsis, hepatocellular dysfunction occurs within 2 hours (Wang, et. al., 
1995), as well as a reduction in bile flow. (Bolder, et. al., 1997) This loss of function 
decreases the amount lidocaine met"ibolites being eliminated by the bile duct, and in 
conjunction with poor renal perfusion, there could be an increase of lidocaine metabolites 
in the serum in the endotoxic model. It has been recently shown in a severe ischemia-
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reperfusion injury rat model that the fluorescence immunoassay used in this experiment, 
is not selective in detecting only MEGX, but also detects other lidocaine metabolites, 
particularly the free, and conjugated forms of hydroxy-MEGX, which accumulated in the 
plasma. (LeClercq, et. al., 1997) If renal perfusion and bile flow, the two main routes of 
metabolite excretion, are lower during sepsis, there will be an accumulation of 
metabolites in the rat. If septic rats have higher levels of lidocaine metabolites in their 
serum due to accumulation the amounts will be higher than what is being generated at 
that time. When analyzed, the immunoassay will detect all the MEGX and hydroxy-
MEGX generated and not excreted, resulting in higher values than control and 
cimetidine. 
Since levels ofMEGX were shown to be elevated during sepsis in our rat model, 
we wanted to see if we could use a lidocaine:MEGX ratio as a marker for drug 
metabolizing capabilities instead of just looking at the metabolite. AB was stated earlier, 
lidocaine clearance was significantly lower in the endotoxin group, whereas MEGX 
formation was higher. Ratios of serum levels of lidocaine:MEGX were significantly 
different for all three groups at 15 minutes . Measurements at this point are more variable 
than measurements of serum ratios taken at a time interval when the clearance and 
metabolite might be reaching a steady state. In this experiment a steady state started to 
occur between 45 and 60 minutes, and a ratio of parent to metabolite might make it 
possible to assess the livers drug metabolizing capabilities, rather than at an earlier time 
point. Elin, et. al. looked to see if there was a difference in parent: metabolite ratios using 
lidocaine, as an assessment tool to determine liver function in patients with chronic viral 
hepatitis but found no significant difference, which was not surprising since the 
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differences in lidocaine and MEGX concentrations were not significantly different either. 
(Elin, et. al., 1997) Therefore this is a novel approach that needs further examination in 
various other types of disease states, as well as in hypodynamic sepsis, to validate its 
usefulness. 
The two sub-populations of the endotoxin group gained our interest. We 
examined these two groups separately to see if there was any difference between those 
rats that had a drop in blood pressure, compared to those that did not. Both groups had a 
significantly lower clearance of lidocaine, compared to the control group, but were not 
significant compared to each other. Although we did not see a significant effect, there is 
the possibility that there is a significant difference between the shock and non-shock 
animals, and a type II statistical error might have been committed with our small sample 
size. Further experimentation would support the role that altered hemodynamics might 
play in the elimination of lidocaine during septic shock. 
MEGX concentrations between the two sub-populations were significantly higher 
for the non-shock than shock group. This supports the idea previously mentioned in 
regards to the hepatocellular dysfunction inhibiting bilary excretion of the metabolite 
compounds. The renal blood flow in the non-shocked animals most likely is not changed, 
so the accumulation of metabolite could possibly be due to a reduction in bile flow. This 
would lead to an accumulation of MEGX and the free and conjugated forms of hydroxy-
MEGX, which could not be distinguished with the TDx immunoassay. 
In conclusion, endotoxin produces many negative physiologic changes that are 
seen systemically, in specific organs, and cellularly. Endotoxin can cause severe 
hypotension. Endotoxin inhibits the P450 drug-metabolizing enzyme system, which is 
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responsible for removing xenobiotics from the body non-toxically . The specific isoforms 
which, are capable of metabolizing lidocaine, are inhibited by endotoxin. This inhibition 
reduces the clearance of lidocaine from the serum in septic rats, and the systemic effects 
led to an accumulation of lidocaine metabolites in the serum, which can possibly be 
indistinguishable using the TDx analyzer. Due to these conflicting results, the ratio of 
lidocaine:MEGX is being postulated as a possible tool determining drug metabolizing 
capabilities during sepsis, but further validation is needed in this model of hypodynamic 
sepsis. 
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Appendix I 
The metabolism of lidocaine by rat liver microsomes has been studied 
extensively. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990) Lidocaine 
is N-deethylated to give monoethylglycinexylidide (MEGX), its major metabolite. 
(Figure 9) This reaction is catalyzed by various P450 enzymes in the rat liver, but the 
.. 
isoforms which have shown the highest turnover for MEGX formation are largely P450 
2Bl, 2Cl 1, and 3A2. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990) 
Endotoxin administration has been shown to inhibit many P450 isoforms, specifically 
P450 3A2, and 2Cll, (Sewer, et. al., 1996; Morgan, et. al., 1993) in rats, and 2Bl in mice 
(Stanley, et. al., 1991 ), which are the same isoforms that metabolize lidocaine. In this 
study we examined the effects of an acute, lethal dose of endotoxin on the metabolism of 
lidocaine in isolated rat liver microsomes. 
Male Sprague Dawley rats, ranging from 250-550g, were administered endotoxin, 
cimetidine, or no treatment. Cimetidine, 80mg/kg, was injected IP, daily for three days 
prior to surgery, was used as a positive control for inhibition of cytochrome P450. 
(Levine, et. al., 1998) Endotoxin (E. Coli 026:B6 LPS, lot #91608), 45.6 mg/kg, was 
injected IP six hours before the liver was removed and homogenized. 
Rats were sacrificed, and the front two lobes of the liver were excised. Livers 
were weighed and homogenized 1 :3 in phosphate buffered solution (PBS) containing 
NaCl 136.9mM, KC! 2.2 mM, NaH2P04 8.1 mM, KH2P04 1.5 mM, pH 7.4. The 
homogenates were centrifuged at 4°C for 20 minutes at 10,000 x g. Supernatant was 
decanted off, and 5 mL of ice cold PBS was added. The supernatant was then centrifuged 
in a Beckman Ultracentrifuge, using a 42.1 rotor, at 4°C for one hour at 35,000 x g. The 
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supernatant was poured off and discarded. Fifteen mL of ice cold PBS was added, and 
the microsomal pellet was vortexed away from the glycogen, and resuspended using a 
glass homogenizer. The homogenate was centrifuged again, to reduce the amount of 
hemoglobin, at 4°C for one hour at 35,000 x g. Supernatant was discarded, and the pellet 
was resuspended in 7.0 mL of PBS. The microsomal solution was pipetted out into 1.0 
mL aliquiots and frozen at -80°C. Total microsomal protein was determined by 
bicinchoninic acid (BCA) assay. (Smith, et. al., 1985) 
Microsomal solution, 50 µL, was incubated in 0.1 mol/L sodium phosphate 
(NaPi) buffer, pH 7.4, in a final volume of 400 µL, in the presence of 4 mM reduced 
nicotinamide adenine dicucleotide. Lidocaine was then added in a final concentration of 
50 µM. The reaction was incubated at 37°C for 20 minutes and then stopped by the 
addition of 10 µL of 70% perchloric acid. Denatured protein was removed by 
centrifugation, and the supernatant was analyzed for lidocaine and MEGX by the TDx 
analyzer. (Abbott laboratories) 
There was no significant difference between the different treatment groups in the 
amount of lidocaine consumed. The control group consumed 2. 7 nmol of lidocaine, 
while the endotoxin and cimetidine group consumed 3.3, and 2.9 nmol of lidocaine 
respectively. There was no significant difference in MEGX formation between any of the 
treatment groups. (Figure 10) 
Lidocaine is metabolized by many P450 isoforms, but those that possess the 
highest activity for the catalyzation of lidocaine to MEGX are 2C 11, and 3A2, in rat liver 
microsomes. (Nakamoto, et. al., 1997) ln our experiment we found there was no 
diffference between groups. We expected there to be a significant difference between the 
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endotoxin and untreated groups, as well as between the cimetidine group and the 
untreated group, in the amounts of lidocaine metabolized, and the amount of MEGX 
formed . We had expected to see more lidocaine and Jess MEGX in the endotoxin groups 
because all three of the isoenzymes responsible for lidocaine metabolism are inhibited by 
endotoxin. (Morgan, 1990; Sewer, et. al., 1996) It has been shown in vivo and in the 
perfused rat liver that lidocaine clearance is inhibited by cimetidine. (Bruck, et. al., 1990; 
Fruncillo, et. al., 1983) This decrease in lidocaine clearance can be due to cimetidine 
inhibition of P4502Cl 1, but not 3A2. (Levine, et. al., 1998) In this experiment, we 
expected to see some difference between the control and the cimetidine groups in regards 
to MEGX formation, and lidocaine elimination. The inhibition was expected to be less 
than that seen with endotoxin because of cimetidines incomplete inhibition of all 
lidocaine metabolizing P450 isoforms. 
Previous studies have shown that MEGX formation was much greater than that 
shown in this experiment. (Nakamoto, et. al. 1997; Oda, et. al. , 1989) Our values were 
very minute, between 1-8 x 10-5, while in other studies there was a 100 times greater 
amount of MEGX formed . This comparison with other researchers results leans us to 
believing the microsomes used in the experiment were not as active. The methodologies 
used by these groups worked with microsomes stored in 250 mM sucrose. We stored our 
isolated microsomoes in PBS, as described by Muller, et. al. All other procedures were 
similar, leading us to believe it is this difference in the storage which led to the faulty 
results. (Muller, et. al., 1996) 
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Figure 9. Metabolic pathways of lidocaine. (Drawn from published data. Oda, et. al , 
1989; Chandel, et. al , 1995) 
43 
MEGX 
3-0H Lidocaine Me-OH Lidocain/ 1 
2,6 Xylidin<:;.,~---- GX 
l 
4-0H 2,6 Xylidine 
44 
Figure 10. In vitro MEGX concentrations (ng/ug protein). 50 µM Lidocaine was added 
to 50 µL of microsomes containing 50 µL PBS, 0. lM NaPi, and 2mM NADH, and 
incubated at 37°C for 20 minutes. Assay was centrifuged and supernatant was analyzed 
for MEGX concentration by flourescence immunoassay. Values represent pmoles of 
MEGX formed per minute per µg protein. 
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Appendix II 
Infections in humans and animals are capable of altering the expression and 
activity of the enzyme isoforms that make up the cytochrome P450 drug metabolizing 
enzyme gene superfamily. There are at least 14 families and 26 sub-families which 
belong to the P450 enzyme system in mammals. (Nelson, et. al., 1996) Many 
xenobiotics as well as physiologically produced substrates are bioactivated or 
biotransformed, or detoxified by this enzyme system, so the regulation of this system is 
very important. Although there are many different genes, only a select few are 
responsible for the metabolism of most drugs. In humans these isoforms are P450's 1A2, 
2A6, 2C8, 2C9, 2Cl 1, and 3A4. (Spatzenegger, et. al., 1995) In rodents and other 
mammals, there are homologous counterparts to these isoenzymes. (Imaoka, et. al, 1990) 
Potential alterations in these enzymes as a result of an infection have the potential to 
change serum levels of therapeutic compounds. 
In a serious infection, like sepsis, there is an overwhelming inflammatory 
response that occurs on the systemic level. This systemic inflammatory response is 
correlated with the generation and release of various cytokines. (Jacobs, et. al., 1989) 
These cytokines are capable of altering the hepatic metabolism of drugs through 
suppression of the aforementioned P450 isoforms, making the understanding how these 
cytokines alter P450 activity clinically relevant. 
Endotoxin, or lipopolysaccharide (LPS), found on the cell wall of the gram-
negative bacteria, is used as a model for bacterial sepsis. Endotoxin administration 
causes activation of the inflammatory response system, which results in high 
concentrations of cytokines released into the bloodstream. (Cannon, et. al, 1990; Hack, et. 
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al, 1989) In the endotoxin model, these high concentrations of cytokines, as well as the 
LPS itself, centralize near the hepatocyte. (Billiar, et. al, 1992) 
The release of tumor necrosis factor a (TNF-a) from macrophages is the primary 
step in response to LPS administration in animals. (Lowry, 1993) TNF-a then up-
regulates the release of itself and interleukin- I (IL-1 ), which in conjunction with TNF-a, 
stimulates the release of interleukin-6 (IL-6), as well as many other mediators of the 
inflammatory system. Since the liver has its own macrophages, the Kupffer cells, 
endotoxin can act directly in the liver to generate the immune response, releasing 
cytokines directly at the liver. Results of this are the high levels ofliver localized 
cytokines. (Billiar, et. al. 1992) 
Overall administration ofLPS has effects on the activity and regulation of the 
P450 system. LPS causes decreases in P450 protein and mRNA expression in rat 
hepatocytes. (Carlson, et. al, 1996; Sewer, et. al., 1997) Although the effect can be 
through the endotoxin acting directly on these hepatocytes to cause these changes, the 
activation of the Kupffer cells, and subsequent release of cytokines, may also mediate 
these changes. Since LPS causes a rise in cytokine levels, and these cytokines play a role 
in the inflammatory response, the effects of certain cytokines on P450 regulation have 
been described. 
Several studies have described the effects of independent administration of TNF-
a, IL-1 , and IL-6 on drug metabolism and P450 levels have been looked at. In the rat 
.. 
model, total levels of P450 are suppressed by TNF-a, and IL-1. (Pous, et. al., 1990; 
Wright, et. al., 1991; Nadin, et. al., 1995) Rats treated with TNF-a had decreased levels 
of activity, mRNA expression, and protein content of P450's 2C 11 and 3A2 after one and 
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three days of treatments . (Nadin, et. al., 1995) Further evidence supporting the 
involvement of TNF-a in the suppression of some P450 isoforms came from the 
administration of pentoxifylline to rats. Pentoxifylline blocks TNF-a formation in 
response to LPS. When administered to rats given LPS, the LPS induced suppression of 
2El and 3A2 in rat liver was blocked. (Monshouwer, et. al., 1996) 
Administration of IL-1 is also selective for inhibitio·n of various isoforms of P450. 
A single dose of IL-1 to rats suppressed the total hepatic P450 content as well as the 
metabolizing activities of many xenobiotics, 24 hours after administration. (Kurokohchi, 
et. al., 1992) Daily doses of IL-la elicited a reduction of activity, but not expression of 
P450 3A2, 2Cl 1, and lAl in male rats. (Ferrari, et. al., 1993) Decreases in the 
expression of 2C 11 and 3 A2 after two IL-1 injections were also seen in the male rat liver 
after 24 hours. (Morgan, et. al., 1994) 
IL-6 also can alter the activity and expression of P450. (Wright, et. al, 1991 ; 
Morgan, et. al. 1994; Chen et. al., 1992) Suppression of the protein and mRNA of P450 
2Cl 1, and the mRNA of 2El , was seen after three injections of IL-6. (Morgan, et. al. 
1994) There were no alterations in the levels of P450 3A2 or 2El mRNA or protein after 
24 hours . (Morgan, et. al. 1994) 
The effect cytokines have on cells, and the regulation and activity of intracellular 
processes, are through receptor activated second messengers. The response each of these 
cytokines previously mentioned has on hepatocytes is played out through these second 
messengers. One type of second m.essenger in liver cells are sphingolipids. Ceramide, a 
product of the hydrolysis of sphingomyelin, by sphingomyelinase, is thought to act as a 
second messenger in many cell types. lt has been shown that IL-1 and TNF-a activate 
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sphingomyelinase to produce ceramide. (Hannun, et. al. , 1994) Incubation of hepatocytes 
with either sphingomyelinase or a short chain ceramide, (C2-ceramide) has shown 
suppression of 2C 11, mimicing the effects of IL-1. (Chen, et. al., 1995) This suggests 
that sphingolipids can act in determining the expression of hepatic P450 genes. The 
question still remains as to whether it is ceramide carrying out the effects in the cell, or if 
it is the products, sphingosine and sphingosine-1-phosphate, of ceramide metabolism. 
The metabolites of ceramide have been researched, and it has been shown that at doses of 
IL-1, capable of suppressing 2C 11, and maximize the activity of sphingomyelinase, 
ceramide is barely detectable. (Chen, et. al., 1995) 
Another second messenger in cells is nitric oxide (NO). NO is a product of nitric 
oxide synthase, which forms NO from arginine. There are two forms of nitric oxide 
synthase. The one relevant to LPS, is the inducible form that is found in macrophages 
and hepatocytes upon an inflammatory stimulation. (Bredt, et. al., 1994; Morris, et. al., 
1994) NO is capable of binding to any heme containing protein, and cytochrome P450 is 
no exception. Upon binding to P450, the catalytic activity is altered, and the inhibition is 
only partially reversible. (Wink, et. al. , 1993) Several studies have investigated the role 
of P450 inhibition by nitric oxide after LPS administration. The addition of a nitric oxide 
synthase inhibitor to the drinking water of rats four days before LPS administration 
partially prevented a decline of2Bl and 2B2 activity, and mRNA, seen in endotoxemic 
animals pretreated with phenobarbital to induce the concentrations of 2B 1 and 2B2. 
(Khatsenko, et. al. , 1993 ; Khatsenko, et. al. , 1994)) It was postulated from these 
experiments that the decrease in P450 catalytic activity is due to the increase of NO in the 
cell, and this increase of NO also might be a contributing factor to the degradation of the 
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P450 enzymes. (Khatsenko, et. al., 1993) Muller, et. al. also showed that the the 
administration of either two different nitric oxide synthase inhibitors in normal or 
phenobarbital treated rats inhibited the decreases seen in the LPS generated decline of 
P450 content, as well as ethylmorphine N-demethylase, and the metabolism of 
midazolam. (Muller, et. al, 1996) In rats, the enzymes involved in the metabolism of 
ethyl morphine are P4502B1, 2C6, 2Cl 1, and 3A2, so many of the isoforms responsible 
for drug metabolism are inhibited by NO. 
In summary, LPS causes a widespread systemic inflammatory response. This 
response is mediated by various cytokines, and the effects of these cytokines on different 
cell types is degradative. It has been shown in hepatocytes, endotoxin, can interact and 
alter the expression and activity of the P450 system. Other studies have shown 
corraborative evidence that the mediators IL-1, IL-6, and TNF-a, all have the ability to 
suppress different P450 isoforms important to the metabolism of drugs. The formation of 
second messengers from receptor mediated binding of these cytokines has also been 
investigated. Increased levels of ceramides have been shown to inhibit P450 expression. 
Nitric oxide has also been suggested as a culprit in the inhibtion of catalytic activity of 
the P450 enzymes. In closing, although much work has been done to examine the 
mechanisms of regulation of the P450 system during endotoxemia, there is much more 
research of unanswered questions to be done. 
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Appendix III 
Conclusions and Future Investigations 
Conclusions: 
1.) An LD 100 dose of endotoxin causes severe hypotension in rats after eight hours. 
2.) Lidocaine clearance is decreased in this rat model of endotoxin induced septic shock, 
compared to controls, after 25 minutes of lidocaine administration. 
3.) Increased concentrations of the metabolite MEGX was seen in septic rats, compared 
to controls, 120 minutes after administration of lidocaine. 
4.) Levels of MEGX increased during septic shock, and a definitive reason for this 
increase is still unknown, since the TDx assay for MEGX also detects hydroxy-
MEGX (LeClercq, et. al. , 1997). The lidocaine:MEGX ratio could be a useful 
indicator of drug metabolism inhibition, but further validation is needed in a model 
where accurate concentrations ofMEGX have been determined. 
Future Investigations: 
1.) It has been shown that the TDx assay for MEGX is also sensitive to hydroxy-MEGX. 
(LeClercq, et. al. , 1997) Examination of the serum concentrations of MEGX and 
hydroxy-MEGX using high performance liquid chromatography to examine the 
concentrations of each of these-t-wo metabolites is needed to determine the actual 
concentrations of metabolites . 
2.) Microsomal amidases are capable of rapidly hydrolyzing MEGX. (Hollunger, et. al., 
1960) Investigation to see whether these amidases are inhibited by endotoxin, would 
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add further explanation to the increase of serum MEGX levels seen in our septic 
model. 
3 .) Reduction in bile flow has been shown in endotoxic rats. (Bolder, et. al., 1997) Since 
bile flow is one possible route for lidocaine metabolite excretion, investigation of the 
role this reduction in bile flow has on the increased levels of MEGX in the serum 
seen in the endotoxic model is needed. 
4.) Since lidocaine is a high extraction compound, blood pressure plays an important role 
on its clearance. Examination of the extent to which severe hypotension alters the 
clearance oflidocaine, and the excretion of MEGX, is necessary. 
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